100 项与 Serbian Seasonal Influenza Vaccine (Torlak-300)(PATH) 相关的专利（医药）
项与 Serbian Seasonal Influenza Vaccine (Torlak-300)(PATH) 相关的文献（医药）
In Torlak we (would) trust: domestic vaccine production in contemporary Serbia.
作者: Marija Brujić
Throughout the era of socialist Yugoslavia, the Institute of Virology, Vaccines and Sera 'Torlak' in Belgrade was a well known producer and exporter of vaccines. After the dissolution of the country, it gradually lost its significance in both global and domestic vaccine markets. However, in Serbian public discourse, Torlak's vaccines are still remembered as of the highest quality. Many people would willingly vaccinate themselves or their children with Torlak's vaccines. But how do overly positive Yugoslav vaccination experiences influence vaccination narratives in contemporary postsocialist Serbia? To answer this question, I analysed electronic word of mouth from 2005 until 2020 from Serbia's main daily news sources. Public narratives on Torlak's vaccine production seem to be a local response and a consequence of global changes in the international vaccine market. Furthermore, this study shows that public calls for the revival of Torlak's vaccine production are part of wider public yearning for 'normal life' in postsocialist Serbia. In this respect, positive memories of Torlak vaccines do not serve as a strategy for dealing with the past. As a special form of Yugo-nostalgia and as a 'material embodiment' of normal life under socialism, narratives represent a strategy for dealing with the present: a therapy for dealing with the 'abnormality' of life in today's Serbia. Contemporary public vaccination attitudes are shaped both by collective memory of the production and administration of Torlak's vaccines in socialist Yugoslavia, and by narratives on Torlak's unfavourable current position. They also reflect wider opinions, hopes and yearning for the restoration of the country's political, health and economic institutions.
This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18-45 years, were enrolled in the trial. On the day of immunization, volunteers were randomly assigned to receive either a single dose of the trivalent seasonal influenza vaccine (15 μg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Subjects were monitored for adverse events through a clinical history and physical examination, and blood was taken for testing at screening and on day 8 to assess vaccine safety. Serum samples obtained before and 21 days after immunization were tested for influenza antibody titers using hemagglutination-inhibition (HAI) and microneutralization (MN) tests. No serious adverse events were reported. Pain and tenderness at the injection site were the most commonly reported symptoms in both vaccine and placebo groups. Overall, serum HAI responses of fourfold or greater magnitude were observed to H1, H3, and B antigen in 80%, 75%, and 70% of subjects, respectively. Seroprotection rates as measured by HAI were also high (100%, 100% and 86.67%, respectively, for H1, H3 and B). Thus, Torlak's seasonal trivalent influenza vaccine was not associated with adverse events, was well-tolerated and immunogenic. It should be further evaluated in clinical trials to provide sufficient safety and immunogenicity data for licensing in Serbia.
2012-01-01·PloS one3区 · 综合性期刊
Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan.
3区 · 综合性期刊
作者: Michael Favorov ; Mohammad Ali ; Aigul Tursunbayeva ; Indira Aitmagambetova ; Paul Kilgore ; Shakhimurat Ismailov ; Terence Chorba
Except during a 1-year period when BCG vaccine was not routinely administered, annual coverage of infants with Bacillus Calmette-Guérin (BCG) in Kazakhstan since 2002 has exceeded 95%. BCG preparations from different sources (Japan, Serbia, and Russia) or none were used exclusively in comparable 7-month time-frames, September through March, in 4 successive years beginning in 2002. Our objective was to assess relative effectiveness of BCG immunization.
We compared outcomes of birth cohorts from the 4 time-frames retrospectively. Three cohorts received vaccine from one of three manufacturers exclusively, and one cohort was not vaccinated. Cohorts were followed for 3 years for notifications of clinical TB and of culture-confirmed TB, and for 21 months for TB meningitis notifications. Prevention effectiveness based on relative risk of TB incidence was calculated for each vaccinated cohort compared to the non-vaccinated cohort. Although there were differences in prevention effectiveness observed among the three BCG vaccines, all were protective. The Japanese vaccine (currently used in Kazakhstan), the Serbian vaccine, and the Russian vaccine respectively were 69%, 43%, and 22% effective with respect to clinical TB notifications, and 92%, 82%, and 51% effective with respect to culture confirmed TB. All three vaccines were >70% effective with respect to TB meningitis.
Potential limitations included considerations that 1) the methodology used was retrospective, 2) multiple risk factors could have varied between cohorts and affected prevention effectiveness measures, 3) most cases were clinically diagnosed, and TB culture-positive case numbers and TB meningitis case numbers were sparse, and 4) small variations in reported population TB burden could have affected relative risk of exposure for cohorts.
All three BCG vaccines evaluated were protective against TB, and prevention effectiveness varied by manufacturer. When setting national immunization policy, consideration should be given to prevention effectiveness of BCG preparations.